Marksans Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/urk12cp53db9ua5dyf9tmeay.pdf

Key Takeaways


U.K. and Europe: The Growth Engine Fires

Mark Saldanha: "Pretty much, like I've always said, you have got to just wait for the business model sometimes to unfold."

North America: Steady Despite Consumer Headwinds

Mark Saldanha: "Obviously, with costs going up, I think medicines are literally the last priority on everyone's mind. Obviously, food and gas become the top priority for everyone else."

Australia and New Zealand: The Nova Engine


Rest of World: Geopolitical Drag, Gradual Recovery

Mark Saldanha: "If you had asked me this question maybe a quarter back, I never thought the war would last this long. I was hoping that the war would be over before the election because of the pressure of the election, but who knows? It didn't happen, so maybe I don't have a crystal ball to predict on geopolitical scenarios."

Margins and Costs: Operating Leverage Absorbs Shocks

Mark Saldanha: "I think our EBITDA should be pretty much in the range of 21%-22%, whatever we performed this year, this quarter. I do see our overall EBITDA being in that same range."

Capital Allocation and Capacity: Building for INR5,000 Crores


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue ambitionTrending toward INR5,000 croresNext three years
Revenue ambitionDoubling revenue from FY26 base to ~INR6,000 croresNext five years
U.S. order bookIncrease from $225 million to $300 millionNext three years
Australia subsidiaryGrow to a $100 million subsidiaryNext three years
Europe top lineReach INR1,000 croresFive years (target still valid)
FY28 revenueINR4,000 croresFY28 (next year)
Full-year EBITDA margin21% to 22% rangeFY27
Gross marginMaintain at 55% to 56%Ongoing; upside if raw material prices cool
U.S. ANDA filingsFile another 5 to 6 ANDAsBy March (next couple of months)
European M&AHoping to conclude a couple of acquisitionsNext 12 months
Manufacturing capacity additionAdd blocks or acquire a plantApproximately 12 months to 1.5 years
Depreciation run rateCurrent increased level is the going run rateNext couple of quarters
DividendBroadly in line with historical ~1/3 of free cash flowFY27 (formal evaluation pending)

Key Metrics

MetricQ2 FY27
Revenue from operations₹940 cr, +30.5% YoY and +11.8% QoQ
Total income₹958 cr, +29.2% YoY
Gross margin58.5%, +135 bps YoY; declined from 59.1% in Q1
EBITDA₹214 cr, +48.3% YoY
EBITDA margin22.8%, +274 bps YoY; ahead of 20–21% guidance range
Profit before tax₹194 cr, +45.1% YoY
Profit after tax₹144 cr, +44.8% YoY; net margin 15%
Effective tax rate25.8%
North America revenue₹421 cr, 44.8% of total, +8.7% YoY
U.K. and Europe revenue₹405 cr, 43% of total, +65% YoY; organic growth ex-acquisitions 49%
Australia and New Zealand revenue₹101 cr, 10.7% of total, +64% YoY
Rest of World revenue₹14 cr, 1.5% of total
U.S. order book$225 mn, target to reach $300 mn within three years
Cash generated from operations (H1)₹322 cr, vs ₹75 cr in H1 FY26; cash conversion 75.2%
Free cash flow (H1)₹275 cr, after capex of ₹46 cr
Net cash position₹1,095 cr as of Sep end; net worth ₹3,367 cr
Working capital cycle (H1)~128 days, reduced from 138 days in FY26
R&D expenditure (H1)2.6% of revenue
OTC vs Rx mix~75% OTC, ~25% Rx